Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study

John Andrew Francis Haughney, P. W. Ind, David Brendan Price, J. P. Rosen, J. Kennelly

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Patient-guided management of asthma using adjustable dosing of budesonide/formoterol in a single inhaler (Symbicort(R)) was compared with fixed dosing in an open-label, multicentre, randomised study. Patients, uncontrolled on an inhaled corticosteroid (ICS) or controlled on an ICS and a long-acting beta(2)-agonist, entered a 4-week run-in period and received budesonide/formoterol (80/4.5 or 160/4.5 mug), 2 inhalations b.i.d. Following randomisation, the fixed-dosing group (n = 764) continued this regimen for a further 12 weeks. The adjustable-dosing group (n = 775) could step down to 1 inhalation b.i.d. if symptoms were controlled, and, at early signs of worsening symptoms, promptly step up to 4 inhalations b.i.d. for less than or equal to2 weeks.

During run-in, National Heart, Lung and Blood Institute symptom-severity grading was maintained in 60% and improved in 31% of patients, clinic peak flow increased from 400 to 419 l/min (P<0.001), and health-retated quality of life (overall MiniAQLQ) improved from 4.6 to 5.4 (P<0.001). Patients effectively used the adjustabte-dosing regimen; 79% reduced budesonide/formoterol dosage and, compared with fixed dosing, the number of inhalations were significantly towered (3.2 vs. 3.8inhatations/day, P<0.05). Both regimens were well tolerated. In both groups, symptom control was maintained or improved in 85-86% of patients, and 94% experienced no treatment failures. Consistent with current guidelines, adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma control at reduced medication doses. (C) 2004 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)464-475
Number of pages11
JournalRespiratory Medicine
Volume98
DOIs
Publication statusPublished - 2004

Keywords

  • Symbicort((R)) Turbuhaler
  • asthma
  • symptom control
  • budesonide
  • formoterol
  • guided self-management
  • adjustable dosing
  • QUALITY-OF-LIFE
  • SELF-MANAGEMENT PLANS
  • PEAK EXPIRATORY FLOW
  • COST-EFFECTIVENESS
  • BUDESONIDE
  • FORMOTEROL
  • EXACERBATIONS
  • TURBUHALER(R)
  • QUESTIONNAIRE
  • DURATION

Cite this

Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. / Haughney, John Andrew Francis; Ind, P. W.; Price, David Brendan; Rosen, J. P.; Kennelly, J.

In: Respiratory Medicine, Vol. 98, 2004, p. 464-475.

Research output: Contribution to journalArticle

@article{7eed9f39d503490abab5cf4ee0267529,
title = "Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study",
abstract = "Patient-guided management of asthma using adjustable dosing of budesonide/formoterol in a single inhaler (Symbicort(R)) was compared with fixed dosing in an open-label, multicentre, randomised study. Patients, uncontrolled on an inhaled corticosteroid (ICS) or controlled on an ICS and a long-acting beta(2)-agonist, entered a 4-week run-in period and received budesonide/formoterol (80/4.5 or 160/4.5 mug), 2 inhalations b.i.d. Following randomisation, the fixed-dosing group (n = 764) continued this regimen for a further 12 weeks. The adjustable-dosing group (n = 775) could step down to 1 inhalation b.i.d. if symptoms were controlled, and, at early signs of worsening symptoms, promptly step up to 4 inhalations b.i.d. for less than or equal to2 weeks.During run-in, National Heart, Lung and Blood Institute symptom-severity grading was maintained in 60{\%} and improved in 31{\%} of patients, clinic peak flow increased from 400 to 419 l/min (P<0.001), and health-retated quality of life (overall MiniAQLQ) improved from 4.6 to 5.4 (P<0.001). Patients effectively used the adjustabte-dosing regimen; 79{\%} reduced budesonide/formoterol dosage and, compared with fixed dosing, the number of inhalations were significantly towered (3.2 vs. 3.8inhatations/day, P<0.05). Both regimens were well tolerated. In both groups, symptom control was maintained or improved in 85-86{\%} of patients, and 94{\%} experienced no treatment failures. Consistent with current guidelines, adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma control at reduced medication doses. (C) 2004 Elsevier Ltd. All rights reserved.",
keywords = "Symbicort((R)) Turbuhaler, asthma, symptom control, budesonide, formoterol, guided self-management, adjustable dosing, QUALITY-OF-LIFE, SELF-MANAGEMENT PLANS, PEAK EXPIRATORY FLOW, COST-EFFECTIVENESS, BUDESONIDE, FORMOTEROL, EXACERBATIONS, TURBUHALER(R), QUESTIONNAIRE, DURATION",
author = "Haughney, {John Andrew Francis} and Ind, {P. W.} and Price, {David Brendan} and Rosen, {J. P.} and J. Kennelly",
year = "2004",
doi = "10.1016/j.rmed.2003.07.010",
language = "English",
volume = "98",
pages = "464--475",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",

}

TY - JOUR

T1 - Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study

AU - Haughney, John Andrew Francis

AU - Ind, P. W.

AU - Price, David Brendan

AU - Rosen, J. P.

AU - Kennelly, J.

PY - 2004

Y1 - 2004

N2 - Patient-guided management of asthma using adjustable dosing of budesonide/formoterol in a single inhaler (Symbicort(R)) was compared with fixed dosing in an open-label, multicentre, randomised study. Patients, uncontrolled on an inhaled corticosteroid (ICS) or controlled on an ICS and a long-acting beta(2)-agonist, entered a 4-week run-in period and received budesonide/formoterol (80/4.5 or 160/4.5 mug), 2 inhalations b.i.d. Following randomisation, the fixed-dosing group (n = 764) continued this regimen for a further 12 weeks. The adjustable-dosing group (n = 775) could step down to 1 inhalation b.i.d. if symptoms were controlled, and, at early signs of worsening symptoms, promptly step up to 4 inhalations b.i.d. for less than or equal to2 weeks.During run-in, National Heart, Lung and Blood Institute symptom-severity grading was maintained in 60% and improved in 31% of patients, clinic peak flow increased from 400 to 419 l/min (P<0.001), and health-retated quality of life (overall MiniAQLQ) improved from 4.6 to 5.4 (P<0.001). Patients effectively used the adjustabte-dosing regimen; 79% reduced budesonide/formoterol dosage and, compared with fixed dosing, the number of inhalations were significantly towered (3.2 vs. 3.8inhatations/day, P<0.05). Both regimens were well tolerated. In both groups, symptom control was maintained or improved in 85-86% of patients, and 94% experienced no treatment failures. Consistent with current guidelines, adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma control at reduced medication doses. (C) 2004 Elsevier Ltd. All rights reserved.

AB - Patient-guided management of asthma using adjustable dosing of budesonide/formoterol in a single inhaler (Symbicort(R)) was compared with fixed dosing in an open-label, multicentre, randomised study. Patients, uncontrolled on an inhaled corticosteroid (ICS) or controlled on an ICS and a long-acting beta(2)-agonist, entered a 4-week run-in period and received budesonide/formoterol (80/4.5 or 160/4.5 mug), 2 inhalations b.i.d. Following randomisation, the fixed-dosing group (n = 764) continued this regimen for a further 12 weeks. The adjustable-dosing group (n = 775) could step down to 1 inhalation b.i.d. if symptoms were controlled, and, at early signs of worsening symptoms, promptly step up to 4 inhalations b.i.d. for less than or equal to2 weeks.During run-in, National Heart, Lung and Blood Institute symptom-severity grading was maintained in 60% and improved in 31% of patients, clinic peak flow increased from 400 to 419 l/min (P<0.001), and health-retated quality of life (overall MiniAQLQ) improved from 4.6 to 5.4 (P<0.001). Patients effectively used the adjustabte-dosing regimen; 79% reduced budesonide/formoterol dosage and, compared with fixed dosing, the number of inhalations were significantly towered (3.2 vs. 3.8inhatations/day, P<0.05). Both regimens were well tolerated. In both groups, symptom control was maintained or improved in 85-86% of patients, and 94% experienced no treatment failures. Consistent with current guidelines, adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma control at reduced medication doses. (C) 2004 Elsevier Ltd. All rights reserved.

KW - Symbicort((R)) Turbuhaler

KW - asthma

KW - symptom control

KW - budesonide

KW - formoterol

KW - guided self-management

KW - adjustable dosing

KW - QUALITY-OF-LIFE

KW - SELF-MANAGEMENT PLANS

KW - PEAK EXPIRATORY FLOW

KW - COST-EFFECTIVENESS

KW - BUDESONIDE

KW - FORMOTEROL

KW - EXACERBATIONS

KW - TURBUHALER(R)

KW - QUESTIONNAIRE

KW - DURATION

U2 - 10.1016/j.rmed.2003.07.010

DO - 10.1016/j.rmed.2003.07.010

M3 - Article

VL - 98

SP - 464

EP - 475

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -